Keyphrases
Adjunctive Therapy
10%
Antibody-dependent Cellular Cytotoxicity
29%
Antibody-mediated
9%
Antigen-specific
10%
B Cells
28%
B-1 Cells
11%
CD64
18%
CD8+ T Cells
22%
Cell Response
10%
Central Memory
9%
Cerebral Malaria
36%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Chronic Active Epstein-Barr Virus
9%
COVID-19
19%
Cytokine Production
12%
Cytotoxicity
11%
Effector Function
11%
Experimental Cerebral Malaria
21%
IL-15 Superagonist
9%
Immune Response
16%
Infected Red Blood Cell
15%
Infectious Diseases
14%
Interleukin-10
10%
Interleukin-15 (IL-15)
17%
Kruppel-like Factor 2 (KLF2)
20%
Lymphocytes
9%
Malaria
43%
Multiple Gene Expression
9%
N-803
9%
Natural Killer
14%
Natural Killer Cell Deficiency
9%
Natural Killer Cell Subsets
9%
Natural Killer Cells
83%
Opioid Use Disorder
9%
Oxycodone
9%
PCR Analysis
9%
People Living with HIV (PLHIV)
9%
Phase 1 Trial
9%
Plasmodium
14%
Plasmodium Falciparum
42%
Plasmodium Infection
14%
Quiescence
12%
Red Blood Cells
11%
STAT1 Pathway
9%
T Cells
28%
Targeting Glutamine Metabolism
9%
Tumor
9%
Vaccine Effectiveness
9%
Viral Infection
13%
Virologic
9%
Immunology and Microbiology
Alveolar Bone
9%
Antibody-Dependent Cell-Mediated Cytotoxicity
29%
Antigen Specificity
10%
Apicomplexa
9%
B Cell
31%
Blood Brain Barrier
12%
Brain Stem
9%
Cell Antibody
9%
Chloroquine
9%
CRISPR/Cas9
9%
Cytokine
10%
Cytokine Production
12%
Cytotoxic T-Cell
29%
Cytotoxicity
16%
Dinoflagellate
9%
Epitope
9%
Epstein Barr Virus
9%
Fc Receptor
10%
Gene Expression Assay
10%
Gingiva
9%
Glutamine
9%
Haplotype
9%
Human Immunodeficiency Virus
9%
Immune Response
16%
Induced Pluripotent Stem Cell
9%
Infectious Disease
12%
Interleukin 10
9%
Interleukin 15
23%
Kruppel Like Factor 2
9%
Life Cycle
9%
Lymphocyte
9%
Malaria Control
9%
Natural Killer Cell
100%
Osteolysis
9%
P53
9%
Parasitemia
8%
Phagocytosis
11%
Phylum
9%
Plasmodium
17%
Plasmodium falciparum
63%
Prostate
9%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Sirolimus
9%
STAT1
9%
Stroma
9%
T Cell
26%
Vascularization
9%
Viral Disease
10%
Viral Replication
9%
Vulnerable Population
9%
